IMR Press / FBE / Volume 9 / Issue 1 / DOI: 10.2741/E790

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Cardiac allograft vasculopathy: Microvascular arteriolar capillaries ("capioles") and survival

Show Less
1 California Medical Innovations Institute, 11107 Roselle Street, San Diego CA 92121, USA
2 Medical Care Center, Laboratory Dr. Stein and Colleagues, Wallstraße 10, 41061 Mönchengladbach, Germany

*Author to whom correspondence should be addressed.

Front. Biosci. (Elite Ed) 2017, 9(1), 110–128;
Published: 1 January 2017

Cardiac allograft vasculopathy (CAV) is a serious complication of heart transplantation in adults and children. Risk factors include human leukocyte antigen mismatches, number and duration of rejection episodes, type of immunosuppression, antibody-mediated rejection, hypertension, hyperlipidemia, obesity, smoking, diabetes, cytomegalovirus infection, mode of donor brain death, donor age and ischemia/reperfusion injury. Endothelial injury and dysfunction in CAV are characterized by changes in adhesion molecules and up-regulation of major histocompatibility class II antigens followed by endothelial activation of complement C4d. Subsequently, activation of the coagulation cascade leads to deposition of fibrin on endothelium followed by proliferation and migration of vascular smooth muscle cells. The development of a special type of microvessels with phenotypic characteristics of arterial capillaries (“capioles”) seems to provide a survival advantage for patients with CAV. Novel therapies of CAV include statins, and heparin-induced extracorporeal low-density lipoprotein apheresis. Bbeta15-42 which is a fibrin peptide has been shown to improve the graft microvasculature and to reduce ischemia/reperfusion-induced damage. Despite these advances, there is a need to identify and stratify individual CAV risk factors, to develop early biomarkers of CAV, and to better decipher the events that lead to antibody-mediated rejection.

Cardiac Allograft Vasculopathy
Reperfusion Injury
Endothelial Dysfunction
Risk Factors
Back to top